Methods for determining expression of NAG tumor rejection antige

Details Methods for determining expression of NAG tumor rejection antige Methods for determining expression of NAG tumor rejection antige

1998-10-23

1999-09-28

Saunders, David

Chemistry: molecular biology and microbiology

Measuring or testing process involving enzymes or...

Involving antigen-antibody binding, specific binding protein...

435 723, 435 724, G01N 3353

Patent

active

059587113

ABSTRACT:
New tumor rejection antigen precursors, and the nucleic acid molecules which code for them, are disclosed. These tumor rejection antigen precursors are referred to as NAG tumor rejection antigen precursors, and the nucleic acid molecules which code for them are referred to as NAG coding molecules. Various diagnostic and therapeutic uses of the coding sequences and the tumor rejection antigen precursor molecules are described.

REFERENCES:
patent: 5620886 (1997-04-01), Britchard
Kawakami, Y, et al. Identification of a human melanoma antigen recognized tumor-infiltrating lymphocytes associated with in vivo tumor rejection. Proc. Natl. Acad. Sci. USA 91:6458-6462, Jul. 1994.
Wolfel, T, et al. Analysis of antigens recognized on human melanoma cells by A2-restricted cytolytic T lymphocytes (CTL). Int. J. Cancer. 55:237-244, 1993.

Affiliated with

Also associated with

Rating

Methods for determining expression of NAG tumor rejection antige does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Methods for determining expression of NAG tumor rejection antige, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for determining expression of NAG tumor rejection antige will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-702124